diagnosis and management of retroperitoneal sarcoma · diagnosis and management of retroperitoneal...

46
Diagnosis and management of retroperitoneal sarcoma SON Update 2017 Andrea J MacNeill, MD MSc FRCSC Surgical Oncologist, BC Cancer Agency Vancouver

Upload: trankhanh

Post on 27-Jun-2019

224 views

Category:

Documents


0 download

TRANSCRIPT

Page 1: Diagnosis and management of retroperitoneal sarcoma · Diagnosis and management of retroperitoneal sarcoma SON Update 2017 Andrea J MacNeill, MD MSc FRCSC Surgical Oncologist, BC

Diagnosis and management of

retroperitoneal sarcoma

SON Update 2017

Andrea J MacNeill, MD MSc FRCSC

Surgical Oncologist, BC Cancer Agency

Vancouver

Page 2: Diagnosis and management of retroperitoneal sarcoma · Diagnosis and management of retroperitoneal sarcoma SON Update 2017 Andrea J MacNeill, MD MSc FRCSC Surgical Oncologist, BC

2

Page 3: Diagnosis and management of retroperitoneal sarcoma · Diagnosis and management of retroperitoneal sarcoma SON Update 2017 Andrea J MacNeill, MD MSc FRCSC Surgical Oncologist, BC

3

Histologic Subtypes of STS

MSKCC STS Database

RP Subtypes (n=684) Extremity Subtypes (n=3,039)

Desmoid (2%)

Fibrosarcoma (1%)

Leiomyosarcoma (21%)

Liposarcoma (59%)

MPNST (3%)

MFH (3%)

Sarcoma-NOS (2%)

SFT/Hemangiopericytoma (2%)

Undifferentiated (1%)

Other (5%)

DFSP (3%)

Desmoid (5%)

Leiomyosarcoma (8%)

Liposarcoma (23%)

MPNST (3%)

MFH (28%)

Synovial (11%)

Other (19%)

Page 4: Diagnosis and management of retroperitoneal sarcoma · Diagnosis and management of retroperitoneal sarcoma SON Update 2017 Andrea J MacNeill, MD MSc FRCSC Surgical Oncologist, BC

4

Outcomes in STS

Catton, O’Sullivan et al., Int J Rad Oncol Biol Phys 1994; 29:1005.

Overall Survival after Resection by

Primary Site of STS

(Princess Margaret Hospital)

Page 5: Diagnosis and management of retroperitoneal sarcoma · Diagnosis and management of retroperitoneal sarcoma SON Update 2017 Andrea J MacNeill, MD MSc FRCSC Surgical Oncologist, BC

5

Local failure kills

• Local failure leading cause of disease-specific mortality

• Anatomic constraints often preclude R0 resection

✓ Complete (R0/1) vs Incomplete (R2)

Page 6: Diagnosis and management of retroperitoneal sarcoma · Diagnosis and management of retroperitoneal sarcoma SON Update 2017 Andrea J MacNeill, MD MSc FRCSC Surgical Oncologist, BC

6

Evolution

of Surgical

Approach to

RPS

Page 7: Diagnosis and management of retroperitoneal sarcoma · Diagnosis and management of retroperitoneal sarcoma SON Update 2017 Andrea J MacNeill, MD MSc FRCSC Surgical Oncologist, BC

7

Extended resection leads to improved

local control

fig 1. Crude cumulative incidence of local

recurrence by period of surgical resection at

a single institution.

Page 8: Diagnosis and management of retroperitoneal sarcoma · Diagnosis and management of retroperitoneal sarcoma SON Update 2017 Andrea J MacNeill, MD MSc FRCSC Surgical Oncologist, BC

8

Extended resection is associated with improved

Gronchi et al., Ann Oncol 2012.

66%

overall survival

48%

Page 9: Diagnosis and management of retroperitoneal sarcoma · Diagnosis and management of retroperitoneal sarcoma SON Update 2017 Andrea J MacNeill, MD MSc FRCSC Surgical Oncologist, BC

9

Extended resection

operative approachPrinciple – liberal resection of all “involved” organs

• Colon

• Kidney

• Psoas fascia

• +/- Duodenum

• +/- Liver capsule

• +/- IVC/iliac vessels

Right side RPS

• Colon

• Kidney

• Psoas fascia

• Distal pancreas + spleen

• +/- Aorta/iliac vessels

• +/- Diaphragm

Left side RPS

Page 10: Diagnosis and management of retroperitoneal sarcoma · Diagnosis and management of retroperitoneal sarcoma SON Update 2017 Andrea J MacNeill, MD MSc FRCSC Surgical Oncologist, BC

10

Page 11: Diagnosis and management of retroperitoneal sarcoma · Diagnosis and management of retroperitoneal sarcoma SON Update 2017 Andrea J MacNeill, MD MSc FRCSC Surgical Oncologist, BC

11

Page 12: Diagnosis and management of retroperitoneal sarcoma · Diagnosis and management of retroperitoneal sarcoma SON Update 2017 Andrea J MacNeill, MD MSc FRCSC Surgical Oncologist, BC

12

Page 13: Diagnosis and management of retroperitoneal sarcoma · Diagnosis and management of retroperitoneal sarcoma SON Update 2017 Andrea J MacNeill, MD MSc FRCSC Surgical Oncologist, BC

13

Page 14: Diagnosis and management of retroperitoneal sarcoma · Diagnosis and management of retroperitoneal sarcoma SON Update 2017 Andrea J MacNeill, MD MSc FRCSC Surgical Oncologist, BC

14

Page 15: Diagnosis and management of retroperitoneal sarcoma · Diagnosis and management of retroperitoneal sarcoma SON Update 2017 Andrea J MacNeill, MD MSc FRCSC Surgical Oncologist, BC

15

Page 16: Diagnosis and management of retroperitoneal sarcoma · Diagnosis and management of retroperitoneal sarcoma SON Update 2017 Andrea J MacNeill, MD MSc FRCSC Surgical Oncologist, BC

16

Page 17: Diagnosis and management of retroperitoneal sarcoma · Diagnosis and management of retroperitoneal sarcoma SON Update 2017 Andrea J MacNeill, MD MSc FRCSC Surgical Oncologist, BC

17

Page 18: Diagnosis and management of retroperitoneal sarcoma · Diagnosis and management of retroperitoneal sarcoma SON Update 2017 Andrea J MacNeill, MD MSc FRCSC Surgical Oncologist, BC

18

Page 19: Diagnosis and management of retroperitoneal sarcoma · Diagnosis and management of retroperitoneal sarcoma SON Update 2017 Andrea J MacNeill, MD MSc FRCSC Surgical Oncologist, BC

19

Page 20: Diagnosis and management of retroperitoneal sarcoma · Diagnosis and management of retroperitoneal sarcoma SON Update 2017 Andrea J MacNeill, MD MSc FRCSC Surgical Oncologist, BC

20

Page 21: Diagnosis and management of retroperitoneal sarcoma · Diagnosis and management of retroperitoneal sarcoma SON Update 2017 Andrea J MacNeill, MD MSc FRCSC Surgical Oncologist, BC

21

How to work up a

retroperitoneal mass

Labs

• CT abdomen preferable to MRI

• CT chest for staging

• Differential renal scan if nephrectomy

anticipated

Imaging

• B-HCG

• AFP

• LDH

• Metanephrines/catecholamines if

appropriate

Page 22: Diagnosis and management of retroperitoneal sarcoma · Diagnosis and management of retroperitoneal sarcoma SON Update 2017 Andrea J MacNeill, MD MSc FRCSC Surgical Oncologist, BC

22

Why

Biopsy? Establish

diagnosis:eliminate

nonoperative

pathology

Page 23: Diagnosis and management of retroperitoneal sarcoma · Diagnosis and management of retroperitoneal sarcoma SON Update 2017 Andrea J MacNeill, MD MSc FRCSC Surgical Oncologist, BC

23

Page 24: Diagnosis and management of retroperitoneal sarcoma · Diagnosis and management of retroperitoneal sarcoma SON Update 2017 Andrea J MacNeill, MD MSc FRCSC Surgical Oncologist, BC

24

Page 25: Diagnosis and management of retroperitoneal sarcoma · Diagnosis and management of retroperitoneal sarcoma SON Update 2017 Andrea J MacNeill, MD MSc FRCSC Surgical Oncologist, BC

25

Page 26: Diagnosis and management of retroperitoneal sarcoma · Diagnosis and management of retroperitoneal sarcoma SON Update 2017 Andrea J MacNeill, MD MSc FRCSC Surgical Oncologist, BC

26

Why

Biopsy? Establish

diagnosis:eliminate

nonoperative

pathology

Identify

histologic

subtype:tailor treatment

strategy

Page 27: Diagnosis and management of retroperitoneal sarcoma · Diagnosis and management of retroperitoneal sarcoma SON Update 2017 Andrea J MacNeill, MD MSc FRCSC Surgical Oncologist, BC

27

How do histologic subtype

and management strategy

AFFECT

RECURRENCE?

Page 28: Diagnosis and management of retroperitoneal sarcoma · Diagnosis and management of retroperitoneal sarcoma SON Update 2017 Andrea J MacNeill, MD MSc FRCSC Surgical Oncologist, BC

28

Local Recurrence

5y LR 24%

10y LR 33%

Page 29: Diagnosis and management of retroperitoneal sarcoma · Diagnosis and management of retroperitoneal sarcoma SON Update 2017 Andrea J MacNeill, MD MSc FRCSC Surgical Oncologist, BC

29

Distant Metastasis

5y DM 21%

10y DM 21.6%

Page 30: Diagnosis and management of retroperitoneal sarcoma · Diagnosis and management of retroperitoneal sarcoma SON Update 2017 Andrea J MacNeill, MD MSc FRCSC Surgical Oncologist, BC

30

Institutional

Management

Strategies:

WDLPS

Page 31: Diagnosis and management of retroperitoneal sarcoma · Diagnosis and management of retroperitoneal sarcoma SON Update 2017 Andrea J MacNeill, MD MSc FRCSC Surgical Oncologist, BC

31

Institutional

Management

Strategies:

LMS

Page 32: Diagnosis and management of retroperitoneal sarcoma · Diagnosis and management of retroperitoneal sarcoma SON Update 2017 Andrea J MacNeill, MD MSc FRCSC Surgical Oncologist, BC

32

Why

Biopsy?

Consider

neoadjuvant

therapy:radiate first

Establish

diagnosis:eliminate

nonoperative

pathology

Identify

histologic

subtype:tailor treatment

strategy

Page 33: Diagnosis and management of retroperitoneal sarcoma · Diagnosis and management of retroperitoneal sarcoma SON Update 2017 Andrea J MacNeill, MD MSc FRCSC Surgical Oncologist, BC

33

Radiation

Therapy

in RPS

Establish

diagnosis:eliminate

nonoperative

pathology

Identify

histologic

subtype:tailor treatment

strategy

EORTC study 62092-22092

STRASS - A phase III randomized study of preoperative

radiotherapy plus surgery versus surgery alone for patients

with Retroperitoneal sarcoma (RPS)

Goal:

• Increase R0 resection rate

• Decrease local recurrence rate

Level 1 evidence of improved local control in

extremity STS, no survival benefit

Page 34: Diagnosis and management of retroperitoneal sarcoma · Diagnosis and management of retroperitoneal sarcoma SON Update 2017 Andrea J MacNeill, MD MSc FRCSC Surgical Oncologist, BC

34

• More accurate targeting of tumour

volume

• Minimal toxicity

• Improved delivery to well-

oxygenated tissues

• Increased likelihood of negative

margin

• Reduced chance of intraoperative

contamination/tumour rupture

Pre-op RT

Page 35: Diagnosis and management of retroperitoneal sarcoma · Diagnosis and management of retroperitoneal sarcoma SON Update 2017 Andrea J MacNeill, MD MSc FRCSC Surgical Oncologist, BC

35

• More accurate targeting of tumour

volume

• Minimal toxicity

• Improved delivery to well-

oxygenated tissues

• Increased likelihood of negative

margin

• Reduced chance of intraoperative

contamination/tumour rupture

• NOT POSSIBLE!

Pre-op RT Post-op RT

Page 36: Diagnosis and management of retroperitoneal sarcoma · Diagnosis and management of retroperitoneal sarcoma SON Update 2017 Andrea J MacNeill, MD MSc FRCSC Surgical Oncologist, BC

36Pre-op

Post-op

Post-op

Page 37: Diagnosis and management of retroperitoneal sarcoma · Diagnosis and management of retroperitoneal sarcoma SON Update 2017 Andrea J MacNeill, MD MSc FRCSC Surgical Oncologist, BC

37

How (not)

to Biopsy? Establish

diagnosis:eliminate

nonoperative

pathology

Targeting

dedifferentiated

areas

Via RP

approach

At sarcoma

referral centre

With expert

pathology

review

Page 38: Diagnosis and management of retroperitoneal sarcoma · Diagnosis and management of retroperitoneal sarcoma SON Update 2017 Andrea J MacNeill, MD MSc FRCSC Surgical Oncologist, BC

38

How (not)

to Biopsy? Establish

diagnosis:eliminate

nonoperative

pathology

Targeting

dedifferentiated

areas

Via RP

approach

At sarcoma

referral centre

With expert

pathology

review

No role for transperitoneal/

laparoscopic/open biopsy

Page 39: Diagnosis and management of retroperitoneal sarcoma · Diagnosis and management of retroperitoneal sarcoma SON Update 2017 Andrea J MacNeill, MD MSc FRCSC Surgical Oncologist, BC

39

Principles

and

Pitfalls

Establish

diagnosis:eliminate

nonoperative

pathology

Identify

histologic

subtype:tailor treatment

strategy

• Best outcomes achieved at high-volume centres

Page 40: Diagnosis and management of retroperitoneal sarcoma · Diagnosis and management of retroperitoneal sarcoma SON Update 2017 Andrea J MacNeill, MD MSc FRCSC Surgical Oncologist, BC

40

Overall Survival – TARPSWG centres

5y OS 67%

10y OS 46%

Page 41: Diagnosis and management of retroperitoneal sarcoma · Diagnosis and management of retroperitoneal sarcoma SON Update 2017 Andrea J MacNeill, MD MSc FRCSC Surgical Oncologist, BC

41

Principles

and

Pitfalls

Establish

diagnosis:eliminate

nonoperative

pathology

Identify

histologic

subtype:tailor treatment

strategy

• Best outcomes achieved at high-volume centres

• All RPS require MDC review

Page 42: Diagnosis and management of retroperitoneal sarcoma · Diagnosis and management of retroperitoneal sarcoma SON Update 2017 Andrea J MacNeill, MD MSc FRCSC Surgical Oncologist, BC

42

Principles

and

Pitfalls

Establish

diagnosis:eliminate

nonoperative

pathology

Identify

histologic

subtype:tailor treatment

strategy

• Large mass ≠ emergency

• Best outcomes achieved at high-volume centres

• All RPS require MDC review

Page 43: Diagnosis and management of retroperitoneal sarcoma · Diagnosis and management of retroperitoneal sarcoma SON Update 2017 Andrea J MacNeill, MD MSc FRCSC Surgical Oncologist, BC

43

Page 44: Diagnosis and management of retroperitoneal sarcoma · Diagnosis and management of retroperitoneal sarcoma SON Update 2017 Andrea J MacNeill, MD MSc FRCSC Surgical Oncologist, BC

44

Principles

and

Pitfalls

Establish

diagnosis:eliminate

nonoperative

pathology

Identify

histologic

subtype:tailor treatment

strategy

• Large mass ≠ emergency

• Incidental finding at laparotomy/inguinal

hernia repair – do not biopsy, avoid mesh

• Best outcomes achieved at high-volume centres

• All RPS require MDC review

Page 45: Diagnosis and management of retroperitoneal sarcoma · Diagnosis and management of retroperitoneal sarcoma SON Update 2017 Andrea J MacNeill, MD MSc FRCSC Surgical Oncologist, BC

45

Page 46: Diagnosis and management of retroperitoneal sarcoma · Diagnosis and management of retroperitoneal sarcoma SON Update 2017 Andrea J MacNeill, MD MSc FRCSC Surgical Oncologist, BC

46

Take home

messages Establish

diagnosis:eliminate

nonoperative

pathology

Identify

histologic

subtype:tailor treatment

strategy

• RPS is a family of diseases

• Management is multidisciplinary and must be

tailored to histology

• Preoperative tissue diagnosis is imperative

• Outcomes have improved with extended

resection, referral to high-volume centres